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ABSTRACT
Objective: Arterial stiffness increases with age, and is
associated with adverse cardiovascular outcome
including increased mortality. The effect of the oral
small molecule SIRT1 activator, SRT2104, on arterial
stiffness was examined in otherwise healthy cigarette
smokers and participants with type 2 diabetes mellitus.
Methods: 24 otherwise healthy cigarette smokers and
15 people with stable type 2 diabetes were randomised
in a double-blind placebo-controlled crossover trial and
received 28 days of oral SRT2104 (2.0 g/day) or
matched placebo. Blood pressure was measured using
non-invasive oscillatory sphygmomanometry. Pulse
wave analysis and velocity were measured using
applanation tonometry at baseline and the end of each
treatment period. Owing to the small sample size and
similar trends for both groups, data for the two groups
were pooled (post hoc analysis).
Results: Compared to placebo, treatment with
SRT2104 was associated with a significant reduction in
augmentation pressure (p=0.0273) and a trend towards
improvement in the augmentation index and corrected
augmentation index (p>0.05 for both). However, no
changes were observed in pulse wave velocity and time
to wave reflection (p>0.05). Systolic and diastolic blood
pressures remained unchanged throughout the study.
Treatment by cohort interaction was not significant for
any of the pulse wave parameters, suggesting that the
response to SRT2104 in otherwise healthy smokers and
people with diabetes was consistent.
Conclusions: SRT2104 may improve measures of
arterial stiffness in otherwise healthy cigarette smokers
and in participants with type 2 diabetes. Definitive
conclusions are not possible given the small sample
size and exploratory nature of this analysis.
Trial registration number: NCT01031108.
INTRODUCTION
The enzyme sirtuin (silent mating-type infor-
mation regulation 2 homologue) 1 (SIRT1)
belongs to the sirtuin family of nicotinamide
adenine dinucleotide-dependent histone dea-
cetylases and is highly expressed in the vascu-
lar endothelium.1 In addition to other
characteristics, its activation is associated with
improved endothelial function2 and inhib-
ition of atherogenesis.3 Particular interest has
been focused on the potential of therapeutic
SIRT1 activators to act as anti-ageing agents.
Arterial stiffness rises with age and is recog-
nised to be an independent predictor of
KEY QUESTIONS
What is already known about this subject?
▸ Among the seven known sirtuins, SIRT1 has
been identified as the most critical modulator of
vascular function. Animal and laboratory studies
have amply demonstrated its prominent role in
the regulation of vascular homeostasis and dis-
eases. However, little is known about their direct
vascular effects in man.
What does this study add?
▸ The present study has provided evidence that
suggests treatment with the oral SIRT1 activator,
SRT2104, may lead to an improvement in mea-
sures of arterial compliance in otherwise healthy
cigarette smokers and people with type 2 dia-
betes. The exact mechanism of this improved
arterial compliance and the effects of prolonged
treatment with SRT2104 on vascular health
remain to be elucidated.
How might this impact on clinical practice?
▸ Given that aortic stiffness and endothelial function
are key factors in predicting cardiovascular out-
comes, identification of novel pharmacological
means of improving these predictive parameters is
important and highly relevant in populations with
known cardiovascular risk factors.
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cardiovascular risk.4 In particular, elevations in pulse
pressure and aortic stiffness are associated with
increased risk of coronary events and overall mortality.5
Indeed, central aortic stiffness is associated with the
presence of coronary atherosclerosis and ischaemic
heart disease.6
Cigarette smoking and diabetes mellitus are signiﬁcant
risk factors for the development of cardiovascular
disease. A wealth of data has established a strong correl-
ation between diabetes and cigarette smoke exposure
with increased aortic stiffness, endothelial dysfunction
and cardiovascular risk.7–10 New pharmacological strat-
egies that improve arterial compliance would therefore
be highly relevant to these groups at increased cardiovas-
cular risk.
The aims of the present study were to assess the effect
of the oral SIRT1 activator, SRT2104, on measures of
arterial compliance in otherwise healthy cigarette
smokers and patients with type 2 diabetes. It was
hypothesised that SIRT1 activation in these ‘at risk’
groups could lead to an improvement in arterial compli-
ance and therefore reduce their cardiovascular risk.
METHODS
The study was approved by the Berkshire Research
Ethics Committee, received Clinical Trial Authorisation
from the Medicines and Healthcare products Regulatory
Agency (MHRA, UK), and was conducted at the MHRA
phase I accredited Wellcome Trust Clinical Research
Facility at the Royal Inﬁrmary of Edinburgh, UK
between June 2010 and September 2011 (EudraCT #:
2009-016765-28; Clinical trials identiﬁer: NCT01031108).
Written informed consent was obtained from each vol-
unteer and the study was carried out in accordance with
the declaration of Helsinki.
Study participants
Twenty-four otherwise healthy cigarette smokers and 15
participants with stable type 2 diabetes, aged between 18
and 70 years, were eligible for the study. Healthy cigar-
ette smokers were required to have smoked ≥10 cigar-
ettes daily for at least 1 year. Participants with type 2
diabetes were non-smokers and were selected on the
basis of having a diagnosis of type 2 diabetes mellitus for
at least 6 months prior to inclusion in the study, with no
change in medications having been made for at least the
preceding 3 months, a fasting blood glucose
≤13.9 mmol/L (250 mg/dL) and diabetes control and
complications trial-aligned HbA1c<9% (75 mmol/mol)
on screening. Exclusion criteria included the presence
of signiﬁcant comorbidities, chronic illness, renal or
liver impairment, history of gastrointestinal diseases or
previous surgical procedures that would inﬂuence drug
absorption, history of alcoholism, history of neoplastic
disease within the last 5 years, a positive urinary test for
recreational drugs, pregnancy and participation in other
clinical trials or blood donation within the last
3 months. Patients with type 2 diabetes mellitus on ACE
inhibitors, antiplatelet or anticoagulant therapies were
excluded from the study. Tests for pregnancy (serum
human chorionic gonadotropin (HCG) concentrations
at screening and urinary HCG concentrations at study
visits) were conducted on all female participants of
childbearing potential.
Study design
This was a prospective double-blind randomised
placebo-controlled cross-over study. Participants were
randomised to receive 2.0 g daily of oral SRT2104 or
matched placebo (Sirtris, a GSK company,
Massachusetts, USA) for a 28-day period, followed by
cross-over to the alternate study arm for a further
28 days, giving a total dosing duration of 56 days. An end
of study visit was conducted at day 70 with a telephone
call follow-up on day 86. Measures of arterial stiffness
were undertaken prior to and at the end of each 28-day
trial period. Figure 1 outlines participant enrolment,
intervention allocation, follow-up and data analysis for
both groups.
All studies were performed in a quiet temperature
controlled (22–25°C) room. Participants were fasted and
asked to refrain from smoking for 10 h, and abstain
from caffeine and alcohol for 24 h prior to assessment.
Participants remained supine for at least 30 min before
any recordings were started. Systolic and diastolic blood
pressures were recorded using a non-invasive oscillatory
sphygmomanometer (Omron705 IT, Omron Healthcare
Europe, the Netherlands).
Pulse wave analysis of the radial artery was performed
at the wrist using micromanometer applanation tonome-
try (Millar Instruments, Texas, USA) and the
SphygmoCor system (AtCor Medical, Sydney, Australia)
in accordance with the manufacturer’s recommenda-
tions. Brieﬂy, pulse wave analysis derives an aortic pulse
pressure waveform from the radial artery wave via a
mathematical transfer function. The arterial pressure
waveform is a composite of the forward pressure wave
created by ventricular contraction and a reﬂected wave
generated by peripheral vascular resistance.11 The aug-
mentation pressure is the pressure difference between
the second and ﬁrst systolic peaks. The augmentation
index, augmentation pressure as a percentage of the
pulse pressure, is a measure of systemic arterial stiffness
and wave reﬂection. Corrected augmentation index
represents the augmentation index corrected for heart
rate.12 The time to wave reﬂection declines with increas-
ing arterial stiffness, and provides a surrogate measure
of aortic pulse wave velocity.13 At least three independ-
ent waveform analyses were obtained from each partici-
pant, with measurements only accepted on meeting
SphygmoCor quality control criteria. Pulse wave velocity
was calculated by measuring the time for the pulse wave
to travel between the carotid and femoral arteries. The
operator performing the analysis was kept constant for
each participant throughout the study.
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Blood sampling
Venous blood samples were collected at fortnightly inter-
vals to measure haematological and biochemical analytes
including full blood count, coagulation proﬁle, liver and
renal function, creatine kinase, lactate dehydrogenase
and lipid proﬁle. Analyses were conducted by the regional
clinical haematology and biochemistry reference lab-
oratories using an automated haematology analyser
(XE2100, Sysmex Corporation ( Japan) and ACL TOP,
Instrumentation Laboratory), an automated chemistry ana-
lyser using colorimetric, kinetic and enzymatic ultraviolet
and colour assays (AU2700/AU640 analysers, Beckman
and Coulter), ion selective electrodes (sodium, potassium
and chloride assays) and two point and multiple point rate
assays (Ortho Clinical Vitros 250 analyser, USA).
Data analysis and statistics
Data were analysed, where appropriate, using repeated
measure analysis of covariance on the change from
baseline for all parameters. Initially, analyses were con-
ducted separately on cohorts. As a result of the small
sample size and similar trends for the two cohorts, these
data were pooled post hoc. Treatment differences were
investigated in a model adjusting for baseline, period,
treatment by period and treatment by cohort using SAS
for UNIX (V.9.1.3 or higher) (SAS Institute, Cary, North
Carolina, USA). Unless stated otherwise, values are
expressed as mean±SD. Tests for treatment effect were
two-sided with a signiﬁcance level of 0.05.
RESULTS
Baseline characteristics
Participants in the study had a mean age of 45±15 years
and were predominantly male (68%). Participants in the
type 2 diabetes cohort were older (mean age 58±8 years)
when compared with the participants in the otherwise
healthy smokers group (mean age 38±13 years). All par-
ticipants were normotensive with comparable systolic
Figure 1 Consolidated Standards of Reporting Trials flow diagram representing participant enrolment, intervention allocation,
follow-up and data analysis. (A) Recruitment of otherwise healthy cigarette smokers; (B) participants with type 2 diabetes
mellitus.
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and diastolic blood pressures at baseline (table 1). No
clinically signiﬁcant changes in haematological or bio-
chemical analytes occurred throughout the study.
Biochemical measures of renal function (serum urea,
creatinine and electrolytes) were within normal limits at
baseline and remained unchanged with placebo and
treatment with SRT2104 in both subgroups (table 2).
Blood pressure
Resting systolic and diastolic blood pressures remained
unchanged throughout the study with no signiﬁcant dif-
ferences between treatment and placebo treatment
periods.
Pulse wave analysis and velocity
In a combined analysis of otherwise healthy cigarette
smokers and participants with type 2 diabetes, a reduc-
tion in the augmentation pressure was observed in parti-
cipants receiving SRT2104 compared with placebo
(mean change from baseline: SRT2104−1.60 (5.304) vs
placebo−0.06 (4.205); p=0.0273) and a trend towards
improvement in the augmentation index (mean change
from baseline in AIx: placebo–0.64 (8.361) vs SRT2104
−3.47 (9.728); p=0.0813) and the corrected augmenta-
tion index (mean change from baseline AIx75: placebo
−2.2−(7.453) vs SRT2104−4.84 (9.299); p=0.0747)
(ﬁgure 2A). Pulse wave velocity and time to wave reﬂec-
tion remained unchanged between placebo and treat-
ment arms (p>0.05 for both parameters; ﬁgure 2B). The
effects of SRT2104 administration on measures of arter-
ial compliance were consistent across the two cohorts.
For example, in the SRT2104 arm, mean augmentation
index at 75 bpm was reduced for healthy smokers and
participants with type 2 diabetes (−4.97 vs −4.63,
respectively). Measures of arterial compliance and stiff-
ness for the individual cohorts have been presented in
the online supplementary table S1. A statistical inter-
action between cohort and treatment was not observed
(p>0.05 for all variables tested).
Tolerability and safety
Participants in both study groups (healthy cigarette
smokers and patients with type 2 diabetes) tolerated the
study medication well. There were no meaningful
Figure 1 Continued
4 Venkatasubramanian S, Noh RM, Daga S, et al. Open Heart 2016;3:e000402. doi:10.1136/openhrt-2016-000402
Open Heart
 o
n
 27 M
arch 2019 by guest. Protected by copyright.
http://openheart.bmj.com/
O
pen Heart: first published as 10.1136/openhrt-2016-000402 on 17 M
ay 2016. Downloaded from
 
differences in the number of adverse events between
active treatment and placebo. All reported adverse
events were mild in intensity and resolved without any
intervention or sequelae (table 3). Headaches occurred
with nearly equal frequency in the treatment (SRT2104)
group in both cohorts. Participants with type 2 diabetes
appeared to have more frequent gastrointestinal distur-
bances, such as diarrhoea and nausea in comparison
with healthy smokers. Elevated liver enzymes (alanine
transaminase) resulted in withdrawal of one participant
in the placebo period (day 36) of the diabetes group.
There was only one reported serious adverse event in
the study (SRT2104 arm of healthy cigarette smokers) of
traumatic facial bone fracture that was considered unre-
lated to SRT2104.
DISCUSSION
This randomised double-blinded cross-over study
demonstrated for the ﬁrst time that the oral SIRT1 acti-
vator, SRT2104, may improve arterial compliance in
otherwise healthy cigarette smokers and in people with
type 2 diabetes, without affecting resting measures of
blood pressure.
The assessment of arterial stiffness is increasingly
being used in clinical practice as an independent
measure of cardiovascular risk, including those in high-
risk groups.14 Ageing is associated with an increase in
the stiffness of large elastic arteries induced by structural
alterations in the vascular media such as an increase in
collagen and a decrease in elastin content.15 This
process of biological ageing is accelerated in the pres-
ence of conditions such as diabetes mellitus and hyper-
tension. Semba et al16 and Hofmann et al17 have
demonstrated an association between the presence of
advanced glycation end products and increased arterial
stiffness. Indeed, vascular change induced by cigarette
smoke is considered to be a model of accelerated vascu-
lar ageing. The relationship between tobacco expos-
ure,9 10 18 diabetes7 8 19 20 and increased arterial
stiffness is well established.
Calorie restriction can attenuate age-related arterial
stiffness in animal models through reduced oxidative
stress and altered endothelial nitric oxide bioavailabil-
ity.15 Indeed, calorie restriction can extend lifespan in
lower organisms and mammals, and improves several
metabolic and inﬂammatory parameters.21–26 SIRT1 has
been implicated as an important mediator of lifespan
Table 1 Baseline characteristics of participants who were otherwise healthy cigarette smokers or who had type 2 diabetes
mellitus
Otherwise healthy cigarette
smokers (n=24)
People with type 2
diabetes (n=15)
Mean age (years) 38±13 58±8
Sex
Male 14 (58) 13 (87)
Female 10 (42) 2 (13)
Baseline blood pressure (mm Hg)
Systolic 129±6 133±7
Diastolic 77±2 80±3
Heart rate (bpm) 68±1 77±5
Body mass index (kg/m2) 25±4 30±4
Smoking history
Number of cigarettes/day 17±6 –
Number of pack years 16 –
Urinary cotinine concentration (ng/mL) 1352±950 –
Glycaemic profile
Baseline blood glucose (mg/dL) 85±0 144±2
HbA1c (%) – 7.4±0.8
Concomitant medications
Antiplatelet agents – 5 (33%)
Antihypertensive agents – 3 (20%)
ARB – 2 (13%)
Diuretics – 10 (67%)
Lipid lowering agents – 13 (86%)
Hypolycaemic agents – 4 (27%)
Biguanide – 2 (13%)
Sulfonamide – 1 (6%)
Thiazolidine – 2 (13%)
Insulin
Others
Values expressed as mean±SD.
ARB, angiotensin receptor blocker; HbA1c, haemoglobin A1c.
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extension mediated by calorie restriction.27–29 The
current hypothesis, therefore, was that activation of
SIRT1 may inhibit this process of vascular ageing and be
associated with improvements in arterial stiffness.
No studies have examined the direct effect of SIRT1
activation on measures of arterial compliance. Botden
et al30 were unable to demonstrate an improvement in
augmentation index or central or peripheral blood
Table 2 Changes in biochemical measures of renal function in otherwise healthy cigarette smokers and participants with
type 2 diabetes mellitus administered placebo and SRT2104
Otherwise healthy cigarette smokers
(n=24) Participants with type 2 diabetes (n=15)
Treatment period
1: placebo (n=13)
Treatment period
1: SRT2104 (n=11)
Treatment period
1: placebo (n=8)
Treatment period
1: SRT2104 (n=7)
Day 1 Day 28 Day 1 Day 28 Day 1 Day 28 Day 1 Day 28
Serum urea (mg/dL) 17±3 14±3 11±3 14±3 17±3 17±3 17±6 14±3
Serum creatinine (mg/dL) 0.8±0.1 0.8±0.1 0.7±0.1 0.8±0.1 0.8±0.1 0.8±0.1 0.9±0.1 0.9±0.1
Electrolytes
Sodium (mmol/L) 140±2 140±2 140±2 140±1 139±1 139±3 138±2 139±3
Potassium (mmol/L) 4.0±0.4 4.0±0.4 4.0±0.4 4.0±0.2 4.0±0.3 4.0±0.3 4.0±0.2 4.0±0.4
Chloride (mmol/L) 109±3 107±3 108±3 107±2 104±4 104±3 103±2 104±2
Values expressed as mean±SD.
Figure 2 Effect of treatment with SRT2104 on measures of arterial compliance in otherwise healthy cigarette smokers and
participants with type 2 diabetes mellitus–change from baseline. (A) Pulse wave analysis—augmentation index, corrected
augmentation index, augmentation pressure and time to wave reflection. (B) pulse wave velocity. Solid column: placebo; checked
column: SRT2104. (C) baseline parameters of measures of arterial compliance-combined data.
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pressure following treatment with red wine polyphenols.
In the present study, a 28-day period of treatment with
the oral SIRT1 activator SRT2104 was associated with a
reduction in augmentation pressure and trends towards
improvement in augmentation index and corrected aug-
mentation index. Augmentation pressure and index are
measures of arterial compliance and wave reﬂection
from small to medium sized arteries. As such, they can
be inﬂuenced by endothelial function and a number of
other dynamic and functional factors, such as heart rate
and peripheral circulatory tone.7 14 Preclinical studies
have demonstrated improved vascular function with
SIRT1 activation,2 31–33 and this may explain our obser-
vations of improvement in dynamic measures of arterial
stiffness following short-term administration of SRT2104.
Pulse wave velocity is a more direct measure of arterial
stiffness that is determined by the structural and physical
composition of the arterial wall.8 Changes in pulse wave
velocity are therefore more gradual and less dependent
on the function of small to medium sized arteries. In
Table 3 Summary of treatment emergent adverse events occurring in two or more participants in OHS and participants with
T2DM
Number of events
OHS T2DM
System organ class Adverse event
Placebo
(n=24)
SRT2104
(n=24)
Placebo
(n=14)
SRT2104
n=15)
Any event 18 18 11 14
Nervous system disorders Any event 6 (25%) 11 (46%) 1 (7%) 7 (47%)
Headache 4 6 1 5
Paraesthesia 0 2 0 1
Hypoaesthesia 1 2 0 0
Presyncope 1 1 0 0
Respiratory, thoracic and
mediastinal disorders
Any event 1 (4%) 3 (13%) 0 3 (20%)
Oropharyngeal pain 1 2 0 0
Rhinorrhoea 0 1 0 1
Gastrointestinal disorders Any event 3 (13%) 1 (4%) 4 (29%) 8 (53%)
Diarrhoea 0 0 2 4
Nausea 0 0 1 2
Abdominal pain upper 1 0 0 1
Dyspepsia 0 0 0 2
Reproductive system and breast
disorders
Any event 3 (13%) 1 (4%) 0 0
Dysmenorrhea 3 1 0 0
Musculoskeletal and connective
tissue disorders
Any event 4 (17%) 1 (4%) 0 2 (13%)
Back pain 2 0 0 0
Investigational Any event 2 (8%) 1 (4%) 1 (7%) 1 (7)
Blood bilirubin increased 1 1 0 0
Alanine amino transferase
increased
0 0 1 0
Abnormal liver function
test
0 0 0 1
General disorders and
administration site conditions
Any event 4 (17%) 4 (17%) 2 (14%) 3 (20%)
Influenza like illness 1 0 0 1
Fatigue 1 0 1 1
Infections and infestations Any event 3 (13%) 5 (21%) 3 (21%) 1 (7%)
Nasopharyngitis 0 1 3 0
Rhinitis 2 2 0 0
Upper respiratory tract
infection
1 0 0 1
Injury, poisoning and procedural
complications
Any event 4 (17%) 2 (8%) 3 (21%) 1 (7%)
Contusion 1 0 1 0
Excoriation 1 1 0 0
Skin and subcutaneous tissue Any event 1 (4%) 0 1 (7%) 3 (20%)
Pruritus 0 0 0 2
Metabolism and nutrition disorders Any event 0 1 (4%) 2 (14%) 2 (13%)
Hypoglycaemia 0 0 1 2
Vascular disorders Any event 0 1 (4%) 0 2 (13%)
Flushing 0 0 0 2
OHS, otherwise healthy cigarette smokers; T2DM, type 2 diabetes mellitus.
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the present study, a change in pulse wave velocity was
not observed with SRT2104 administration. This is
perhaps not surprising given the short-time period of
exposure to SRT2104 (28 days) and the brief period of
observation. An improvement in pulse wave velocity
might be anticipated with a longer period of treatment
with SRT2104, to allow more favourable structural
changes in the larger arterial tree.
STUDY LIMITATIONS
Some limitations of this trial should be considered.
Although favourable trends in parameters of arterial
compliance were observed, some did not achieve statis-
tical signiﬁcance. This may partly be attributed to the
trial being designed speciﬁcally to examine the acute
effects of treatment with SRT2104. A longer period of
treatment may be required for beneﬁts to emerge on
variables such as pulse wave velocity that involve struc-
tural changes in the arterial wall. Moreover, the sample
sizes of the two groups examined were small. Two dispar-
ate populations were studied in this trial, in whom the
mechanisms of vascular dysfunction may be very differ-
ent. However, the direction of beneﬁcial effects on treat-
ment with SRT2104 was similar between the two groups,
providing reassurance of a consistency of effect and
allowing the post hoc presentation of the results pooled
across the two groups.
Conclusion
The present study has provided evidence that suggests
treatment with the oral SIRT1 activator, SRT2104, may
lead to an improvement in measures of arterial compli-
ance in otherwise healthy cigarette smokers and people
with type 2 diabetes. The exact mechanism of this
improved arterial compliance and the effects of pro-
longed treatment with SRT2104 on vascular health
remain to be elucidated. Given that aortic stiffness and
endothelial function are key factors in predicting cardio-
vascular outcomes, identiﬁcation of novel pharmaco-
logical means of improving these predictive parameters
is important and highly relevant in populations with
known cardiovascular risk factors.
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